Some benefits from donepezil in Alzheimer’s disease
Date Added: 
    June 20, 2019
      Journal/Publication: 
    British Journal of General Practice
      Publication Date: 
    March 1, 2013
      Issue: 
    63
      Volume: 
    608
      Pages: 
    150
      Type: 
    Meta-analyses, Reviews, and Guidelines
      Format: 
    Article
      DOI (1): 
    10.3399/bjgp13X664333
      Abstract
CLINICAL QUESTION
How effective is exercise-based cardiac rehabilitation on mortality, morbidity, and health-related quality of life (QOL) in patients with coronary heart disease (CHD)?
BOTTOM LINE
Compared to usual care, in medium to longer-term follow-up (≥12 months) exercise-based cardiac rehabilitation was found to be effective in reducing overall and cardiovascular mortality in patients with CHD, and appeared to reduce the risk of hospital admissions in the shorter term (<12 months follow-up). There was no reduction seen in the risk of total myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty.
Text Availability
Free full text
      
          
RPR Commentary
RPR Commentary: This is a summary of the data available to date on the effectiveness of donepezil for treatment of patients with Alzheimer’s Disease. I told patients and their families that if a small improvement in functional abilities would make a huge difference in quality of life (e.g. could remain at home 6 months longer), it is probably worth trying donepezil. Otherwise the expense and side effects are not worth the very small benefit. 5 to 10mg seems to be enough. James W. Mold, MD, MPH